NovaBay Pharmaceuticals Company Profile (NYSE:NBY)

About NovaBay Pharmaceuticals (NYSE:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:NBY
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $42.04 million
  • Outstanding Shares: 15,288,000
Average Prices:
  • 50 Day Moving Avg: $3.27
  • 200 Day Moving Avg: $3.74
  • 52 Week Range: $2.12 - $5.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.9 million
  • Price / Sales: 3.53
  • Book Value: $0.47 per share
  • Price / Book: 5.85
Profitability:
  • EBIDTA: ($10,710,000.00)
Misc:
  • Average Volume: 16,573 shs.
  • Short Ratio: 7.22
 

Frequently Asked Questions for NovaBay Pharmaceuticals (NYSE:NBY)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NBY."

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) released its earnings results on Thursday, August, 11th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.06. The company earned $2.70 million during the quarter, compared to analysts' expectations of $1.76 million. View NovaBay Pharmaceuticals' Earnings History.

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 12-month target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $7.33 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.

What are analysts saying about NovaBay Pharmaceuticals stock?

Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (5/17/2017)
  • 2. Maxim Group analysts commented, "NovaBay reported 4Q16 revenue of 4M, inline with preannouncement back in January. Operating expenses were $6.1M up from the prior quarter's $5.5M. This translated into a net loss of $1.6M or $(0.11) per share. Novabay ended the quarter with $9.5M in cash or about $7M (est.) in cash today... We have adjusted our model to reflect the revenue guidance. We conclude that without a revenue breakout, (driven by additional capital), our model suggests a target valuation in the current range. As such, we maintain our Hold rating." (3/24/2017)

Who are some of NovaBay Pharmaceuticals' key competitors?

Who owns NovaBay Pharmaceuticals stock?

NovaBay Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (0.51%). View Institutional Ownership Trends for NovaBay Pharmaceuticals.

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NovaBay Pharmaceuticals stock cost?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $2.75.

Analyst Ratings

Consensus Ratings for NovaBay Pharmaceuticals (NYSE:NBY) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $7.33 (166.67% upside)

Analysts' Ratings History for NovaBay Pharmaceuticals (NYSE:NBY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017Maxim GroupReiterated RatingHoldLowView Rating Details
3/26/2017HC WainwrightSet Price TargetBuy$6.00MediumView Rating Details
3/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00MediumView Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for NovaBay Pharmaceuticals (NYSE:NBY)
Earnings by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)
Earnings History by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovaBay Pharmaceuticals (NYSE:NBY)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS

Dividends

Dividend History for NovaBay Pharmaceuticals (NYSE:NBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NovaBay Pharmaceuticals (NYSE:NBY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for NovaBay Pharmaceuticals (NYSE:NBY)
Latest Headlines for NovaBay Pharmaceuticals (NYSE:NBY)
Source:
DateHeadline
finance.yahoo.com logoTetraphase Pharmaceuticals, Inc. (TTPH)
finance.yahoo.com - May 19 at 11:31 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 18 at 11:34 PM
seekingalpha.com logoNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 7:25 PM
finance.yahoo.com logoNovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017
finance.yahoo.com - May 4 at 11:27 AM
americanbankingnews.com logoZacks: NovaBay Pharmaceuticals, Inc. (NBY) Given $6.00 Average Price Target by Analysts
www.americanbankingnews.com - May 4 at 9:17 AM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Earns Media Sentiment Score of 0.44
www.americanbankingnews.com - May 3 at 12:20 AM
finance.yahoo.com logoAvenova from NovaBay Pharmaceuticals is Effective for Managing Dry Eye before Refractive and Cataract Eye Surgery
finance.yahoo.com - May 2 at 6:59 PM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Receives Daily Media Sentiment Score of -0.39
www.americanbankingnews.com - April 29 at 7:39 AM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 6:14 PM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Receiving Positive News Coverage, Study Finds
www.americanbankingnews.com - April 21 at 7:17 PM
americanbankingnews.com logo NovaBay Pharmaceuticals, Inc. (NBY) Given $6.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 17 at 6:37 PM
americanbankingnews.com logoNovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 17 at 3:58 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 15 at 8:42 AM
americanbankingnews.com logoNovaBay Pharmaceuticals' (NBY) Hold Rating Reiterated at Maxim Group
www.americanbankingnews.com - April 1 at 11:31 PM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Coverage Initiated by Analysts at Laidlaw
www.americanbankingnews.com - March 31 at 11:50 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Receives "Hold" Rating from Maxim Group
www.americanbankingnews.com - March 30 at 9:10 AM
americanbankingnews.com logoAnalysts Anticipate NovaBay Pharmaceuticals, Inc. (NBY) to Announce ($0.14) Earnings Per Share
www.americanbankingnews.com - March 29 at 12:20 PM
finance.yahoo.com logoAvenova from NovaBay Pharmaceuticals Effective for Painful Eye Condition
finance.yahoo.com - March 28 at 10:11 AM
americanbankingnews.com logoNovaBay Pharmaceuticals, Inc. (NBY) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 27 at 2:49 PM
bloomberg.com logoU.S. Stocks Post Worst Week Since Election as Health Bill Fails
www.bloomberg.com - March 24 at 6:43 PM
finance.yahoo.com logoNovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 10:13 AM
seekingalpha.com logoNovaBay sees 171% jump in 2016 revenues; shares ahead 8%
seekingalpha.com - January 9 at 7:28 PM
streetinsider.com logoNovaBay Pharma (NBY) Notes Positive OCLI Publication on Avenova
www.streetinsider.com - November 29 at 2:40 PM
streetinsider.com logoNovaBay Pharma (NBY) Misses Q3 EPS by 18c
www.streetinsider.com - November 11 at 6:05 PM
seekingalpha.com logoNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 11 at 6:05 PM
seekingalpha.com logoNovaBay regains compliance with NYSE continued listing requirements
seekingalpha.com - October 31 at 1:07 PM
nasdaq.com logoNovaBay Pharmaceuticals Complies With NYSE Listing Requirements
www.nasdaq.com - October 31 at 1:07 PM
seekingalpha.com logoNovaBay pulls in $7M from exercise of warrants
seekingalpha.com - October 3 at 10:55 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of NovaBay Pharmaceuticals, Inc. - NBY
finance.yahoo.com - September 23 at 3:30 PM
feeds.benzinga.com logo15 Stocks Moving In Monday's Pre-Market Session
feeds.benzinga.com - September 19 at 8:39 AM
seekingalpha.com logoNovaBay misses by $0.56, misses on revenue - Seeking Alpha
seekingalpha.com - May 13 at 7:21 AM
finance.yahoo.com logoNovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12
finance.yahoo.com - May 5 at 7:00 AM
benzinga.com logoNovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90% - Benzinga
www.benzinga.com - May 4 at 6:17 AM
streetinsider.com logoNovaBay Pharma (NBY) Enters $12M Securities Purchase Agreement - StreetInsider.com
www.streetinsider.com - April 6 at 12:56 PM
businesswire.com logoNovaBay Pharmaceuticals to Present at 28th Annual ROTH Conference - Business Wire (press release)
www.businesswire.com - March 8 at 1:08 PM
streetinsider.com logoNovaBay Pharma (NBY) Announces $2.83M Private Placement - StreetInsider.com
www.streetinsider.com - February 24 at 7:47 PM
finance.yahoo.com logo4:50 pm NovaBay Pharma confirms $2.83 mln private placement
finance.yahoo.com - February 24 at 4:50 PM
finance.yahoo.com logoNovaBay Pharmaceuticals Announces $2.83 Million Private Placement
finance.yahoo.com - February 24 at 4:48 PM

Social

Chart

NovaBay Pharmaceuticals (NBY) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff